Germany Insulin Drugs And Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Germany Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.

Germany Insulin Drugs And Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Germany Insulin Drugs And Delivery Devices Market Size

Germany Insulin Drugs And Delivery Devices Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 1.11 Billion
Market Size (2030) USD 1.13 Billion
CAGR (2025 - 2030) 0.50 %

Major Players

Germany Insulin Drugs And Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Germany Insulin Drugs And Delivery Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Germany Insulin Drugs And Delivery Devices Market Analysis

The Germany Insulin Drugs And Delivery Devices Market size is estimated at USD 1.11 billion in 2025, and is expected to reach USD 1.13 billion by 2030, at a CAGR of 0.5% during the forecast period (2025-2030).

One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the COVID-19 pandemic. That's why managing or delaying cases of type 2 diabetes became more important than ever before. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.

Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications from COVID-19. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.

Germany is one of the developed countries and advanced in terms of healthcare facilities. Technologies, such as continuous glucose monitoring and insulin infusion pumps, are getting more adopted rapidly in Germany than the other developing countries. Moreover, the reimbursement policy and the pricing policy are highly regulated, which drives the market and increases the adoption rate of new and advanced technologies. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the insulin market's growth.

Germany Insulin Drugs And Delivery Devices Industry Overview

The Germany Insulin Drugs and Delivery Devices Market is moderately consolidated, with few significant and generic players. Mergers and acquisitions between the players recently have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.

Germany Insulin Drugs And Delivery Devices Market Leaders

  1. Medtronic

  2. Ypsomed

  3. Novo Nordisk A/S

  4. Eli Lilly and Company

  5. Sanofi Aventis

  6. *Disclaimer: Major Players sorted in no particular order
Germany Insulin Drugs And Delivery Devices Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Germany Insulin Drugs And Delivery Devices Market News

  • November 2022: Ypsomed's mylife Loop is now authorized to work with Abbott's FreeStyle Libre 3 sensor in Germany. The mylife YpsoPump and the FreeStyle Libre 3, combined with the mylife CamAPS FX algorithm from CamDiab, form an automated insulin delivery system designed to help people with type 1 diabetes to better control their glucose levels and alleviate the burden of daily diabetes management.
  • January 2022: German biotech company Evotec announced it had collaborated with Eli Lilly on drug discovery in metabolic diseases. The total potential value of the collaboration, which will run for three years, is up to USD 1 billion. As part of the collaboration, Evotec will explore potential drug candidates for treating diabetes and chronic liver disease.

Germany Insulin Drugs And Delivery Devices Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Basal or Long-acting Insulins
    • 5.1.1.1 Lantus (Insulin Glargine)
    • 5.1.1.2 Levemir (Insulin Detemir)
    • 5.1.1.3 Toujeo (Insulin Glargine)
    • 5.1.1.4 Tresiba (Insulin Degludec)
    • 5.1.1.5 Basaglar (Insulin Glargine)
    • 5.1.1.5.1 Other drugs
    • 5.1.2 Bolus or Fast-acting Insulins
    • 5.1.2.1 NovoRapid/Novolog (Insulin aspart)
    • 5.1.2.2 Humalog (Insulin lispro)
    • 5.1.2.3 Apidra (Insulin glulisine)
    • 5.1.2.4 FIASP (Insulin aspart)
    • 5.1.2.5 Admelog (Insulin lispro Sanofi)
    • 5.1.3 Traditional Human Insulins
    • 5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard
    • 5.1.3.2 Humulin
    • 5.1.3.3 Insuman
    • 5.1.4 Combination Insulins
    • 5.1.4.1 NovoMix (Biphasic Insulin aspart)
    • 5.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)
    • 5.1.4.3 Xultophy (Insulin degludec and Liraglutide)
    • 5.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)
    • 5.1.5 Biosimilar Insulins
    • 5.1.5.1 Insulin Glargine Biosimilars
    • 5.1.5.2 Human Insulin Biosimilars
  • 5.2 Device
    • 5.2.1 Insulin Pumps
    • 5.2.1.1 Insulin Pump Devices
    • 5.2.1.2 Insulin Pump Reservoirs
    • 5.2.1.3 Insulin Infusion sets
    • 5.2.2 Insulin Pens
    • 5.2.2.1 Cartridges in reusable pens
    • 5.2.2.2 Disposable insulin pens
    • 5.2.3 Insulin Syringes
    • 5.2.4 Insulin Jet Injectors

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk
    • 7.1.2 Sanofi
    • 7.1.3 Eli Lilly
    • 7.1.4 Biocon
    • 7.1.5 Julphar
    • 7.1.6 Medtronic
    • 7.1.7 Ypsomed
    • 7.1.8 Becton Dickinson
  • *List Not Exhaustive
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Insulin Drugs
    • 7.2.1.1 Novo Nordisk
    • 7.2.1.2 Sanofi
    • 7.2.1.3 Eli Lilly
    • 7.2.2 Insulin Delivery Devices
    • 7.2.2.1 Medtronic
    • 7.2.2.2 Ypsomed
    • 7.2.2.3 Becton Dickinson

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Germany Insulin Drugs And Delivery Devices Industry Segmentation

Insulin is mainly used to treat type 1 diabetes but can be used in people with type 2 diabetes if insulin levels remain low despite using other medications. There are different ways to inject insulin into a patient's body, using syringes, pens, pumps, and jet injectors, giving them various options for insulin delivery. The Germany Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.

Drug Basal or Long-acting Insulins Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine) Other drugs
Bolus or Fast-acting Insulins NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro Sanofi)
Traditional Human Insulins Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec and Insulin aspart)
Xultophy (Insulin degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine and Lixisenatide)
Biosimilar Insulins Insulin Glargine Biosimilars
Human Insulin Biosimilars
Device Insulin Pumps Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Need A Different Region or Segment?
Customize Now

Germany Insulin Drugs And Delivery Devices Market Research FAQs

How big is the Germany Insulin Drugs And Delivery Devices Market?

The Germany Insulin Drugs And Delivery Devices Market size is expected to reach USD 1.11 billion in 2025 and grow at a CAGR of 0.5% to reach USD 1.13 billion by 2030.

What is the current Germany Insulin Drugs And Delivery Devices Market size?

In 2025, the Germany Insulin Drugs And Delivery Devices Market size is expected to reach USD 1.11 billion.

Who are the key players in Germany Insulin Drugs And Delivery Devices Market?

Medtronic, Ypsomed, Novo Nordisk A/S, Eli Lilly and Company and Sanofi Aventis are the major companies operating in the Germany Insulin Drugs And Delivery Devices Market.

What years does this Germany Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2024?

In 2024, the Germany Insulin Drugs And Delivery Devices Market size was estimated at USD 1.10 billion. The report covers the Germany Insulin Drugs And Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Germany Insulin Drugs And Delivery Devices Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Germany Insulin Drugs And Delivery Devices Industry Report

Statistics for the 2025 Germany Insulin Drugs And Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Germany Insulin Drugs And Delivery Devices analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.